MeiraGTx Holdings PLC (NASDAQ:MGTX) CEO Alexandria Forbes Sells 47,500 Shares

MeiraGTx Holdings PLC (NASDAQ:MGTX - Get Free Report) CEO Alexandria Forbes sold 47,500 shares of the stock in a transaction dated Tuesday, July 8th. The stock was sold at an average price of $7.97, for a total transaction of $378,575.00. Following the sale, the chief executive officer owned 1,361,483 shares of the company's stock, valued at $10,851,019.51. This trade represents a 3.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

MeiraGTx Price Performance

NASDAQ:MGTX traded up $0.33 during mid-day trading on Tuesday, reaching $8.07. 863,720 shares of the company were exchanged, compared to its average volume of 395,709. MeiraGTx Holdings PLC has a 12 month low of $3.85 and a 12 month high of $8.75. The company has a fifty day moving average of $6.08 and a 200 day moving average of $6.31. The company has a quick ratio of 1.51, a current ratio of 1.53 and a debt-to-equity ratio of 2.34. The stock has a market cap of $648.51 million, a PE ratio of -3.48 and a beta of 1.24.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.13). MeiraGTx had a negative return on equity of 241.05% and a negative net margin of 484.90%. The company had revenue of $1.93 million for the quarter, compared to the consensus estimate of $4.44 million. On average, research analysts anticipate that MeiraGTx Holdings PLC will post -1.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on MGTX shares. Chardan Capital dropped their target price on shares of MeiraGTx from $38.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Wall Street Zen upgraded shares of MeiraGTx from a "sell" rating to a "hold" rating in a research report on Saturday. Finally, Royal Bank Of Canada increased their target price on shares of MeiraGTx from $11.00 to $13.00 and gave the stock an "outperform" rating in a research report on Monday, March 17th.

Institutional Investors Weigh In On MeiraGTx

A number of hedge funds have recently added to or reduced their stakes in MGTX. Rhumbline Advisers grew its holdings in MeiraGTx by 12.3% during the 4th quarter. Rhumbline Advisers now owns 54,891 shares of the company's stock worth $334,000 after acquiring an additional 5,993 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of MeiraGTx by 10.6% in the 4th quarter. Bank of New York Mellon Corp now owns 106,582 shares of the company's stock valued at $649,000 after purchasing an additional 10,217 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of MeiraGTx by 13.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 112,021 shares of the company's stock valued at $682,000 after purchasing an additional 12,961 shares during the last quarter. Privium Fund Management B.V. boosted its stake in shares of MeiraGTx by 5.2% in the 4th quarter. Privium Fund Management B.V. now owns 225,078 shares of the company's stock valued at $1,371,000 after purchasing an additional 11,118 shares during the last quarter. Finally, Corebridge Financial Inc. boosted its stake in shares of MeiraGTx by 11.6% in the 4th quarter. Corebridge Financial Inc. now owns 23,147 shares of the company's stock valued at $141,000 after purchasing an additional 2,405 shares during the last quarter. Institutional investors own 67.48% of the company's stock.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.